<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04840849</url>
  </required_header>
  <id_info>
    <org_study_id>D5290C00007</org_study_id>
    <nct_id>NCT04840849</nct_id>
  </id_info>
  <brief_title>Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults</brief_title>
  <acronym>PK/ADA</acronym>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Nirsevimab in Healthy Chinese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>IQVIA RDS (Shanghai) Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Pharmacokinetics, Safety, Tolerability of&#xD;
      Nirsevimab in Healthy Chinese Adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, randomized, double-blind, placebo-controlled study to evaluate the PK,&#xD;
      safety and tolerability, and ADA of nirsevimab when administered as a single fixed IM dosage&#xD;
      to healthy Chinese adult subjects. Enrolment is planned at a single study center in China.&#xD;
      Approximately 24 subjects will be randomly assigned in a 3:1 ratio to receive nirsevimab (n =&#xD;
      18) or placebo (n = 6). All subjects will be followed for approximately 150 days after dosing&#xD;
      to assess safety, PK, and ADA response.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">November 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summary of nirsevimab serum concentrations</measure>
    <time_frame>Through Day 151</time_frame>
    <description>The serum concentration data and the estimated PK parameters will provide information on the time course and extent of nirsevimab serum exposure in the study population following a single administration. Pharmacokinetic parameters will be calculated using the Phoenix WinNonlin software using a noncompartmental approach.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters - Cmax (maximum observed concentration)</measure>
    <time_frame>Through Day 151</time_frame>
    <description>The serum concentration data and the estimated PK parameters will provide information on the time course and extent of nirsevimab serum exposure in the study population following a single administration. Pharmacokinetic parameters will be calculated using the Phoenix WinNonlin software using a noncompartmental approach.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters - Tmax (time to Cmax)</measure>
    <time_frame>Through Day 151</time_frame>
    <description>The serum concentration data and the estimated PK parameters will provide information on the time course and extent of nirsevimab serum exposure in the study population following a single administration. Pharmacokinetic parameters will be calculated using the Phoenix WinNonlin software using a noncompartmental approach.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameters - AUC0-150 (area under the concentration-time curve from time 0 to 150 days)</measure>
    <time_frame>Through Day 151</time_frame>
    <description>The serum concentration data and the estimated PK parameters will provide information on the time course and extent of nirsevimab serum exposure in the study population following a single administration. Pharmacokinetic parameters will be calculated using the Phoenix WinNonlin software using a noncompartmental approach.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of all treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (TESAEs), adverse events of special interest (AESIs), and new onset chronic diseases (NOCDs). Clinical laboratory assessments, vital signs</measure>
    <time_frame>Through Day 151</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ADA to nirsevimab in serum</measure>
    <time_frame>Through Day 151</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Evaluate PK Profile</condition>
  <arm_group>
    <arm_group_label>Nirsevimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nirsevimab single dose IM injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo single dose IM injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>nirsevimab</intervention_name>
    <description>Drug: injection, a single fixed IM dose on day 1 only.</description>
    <arm_group_label>Nirsevimab</arm_group_label>
    <other_name>MEDI8897</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: injection, 0.9% (w/v) saline, a single fixed IM dose on day 1 only.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 to 45 years&#xD;
&#xD;
          2. Weight ≥ 45 kg and ≤ 110 kg and Body Mass Index of 19 to 26 kg/m2&#xD;
&#xD;
          3. Healthy Chinese subjects (both male and female)&#xD;
&#xD;
          4. Normotensive&#xD;
&#xD;
          5. Normal electrocardiogram (ECG) within 28 days prior to Day 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Acute illness at study entry (pre-dose on Day 1)&#xD;
&#xD;
          2. Fever ≥99.5°F (37.5°C) on day of dosing&#xD;
&#xD;
          3. Any drug therapy within 14 days prior to Day 1 (except contraceptives).&#xD;
&#xD;
          4. Receipt of immunoglobulin or blood products within 6 months prior to study entry.&#xD;
&#xD;
          5. Receipt of any investigational drug therapy within 120 days prior to investigational&#xD;
             product dosing or planned to receive any investigational drug therapy within 150 days&#xD;
             after investigational product dosing.&#xD;
&#xD;
          6. Previous receipt of any marketed or investigational mAb.&#xD;
&#xD;
          7. Previous vaccination against RSV.&#xD;
&#xD;
          8. History of immunodeficiency or receipt of immunosuppressive medications during the&#xD;
             prior year.&#xD;
&#xD;
          9. History of asthma.&#xD;
&#xD;
         10. History of autoimmune disorder.&#xD;
&#xD;
         11. Evidence of any systemic disease on physical examination.&#xD;
&#xD;
         12. Evidence of infection with hepatitis A, B, or C virus, syphilis, or human&#xD;
             immunodeficiency virus.&#xD;
&#xD;
         13. Any clinically significant abnormal laboratory assessments at screening.&#xD;
&#xD;
         14. Pregnant or nursing mother.&#xD;
&#xD;
         15. Alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 8, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2021</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PK</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>Nirsevimab</keyword>
  <keyword>healthy Chinese Adults</keyword>
  <keyword>Respiratory Syncytial Viral (RSV)</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.&#xD;
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

